RDHL Redhill Biopharma Ltd.

+0.11  (+2%)
Previous Close 6.69
Open 6.7
Price To Book 4.36
Market Cap 173478520
Shares 25,511,547
Volume 82,955
Short Ratio
Av. Daily Volume 124,044

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial to be initiated mid-2019.
Nontuberculous mycobacteria (NTM) infections
Phase 2a enrollment to be completed mid-2019.
Phase 1/2 poster presentation at EORTC-NCI-AACR November 16, 2018.
Refractory or relapsed multiple myeloma - cancer
NDA resubmission announced November 1, 2017. Noted December 5, 2017 that an Incomplete Response Letter has been received from the FDA and termination of license agreement with IntelGenx Corp.
Phase 3 data released July 30, 2018. Primary endpoint met but further trial required.
Crohn’s disease
Phase 3 trial met primary endpoint. NDA filing 1H 2019.
H. pylori
Phase 3 top-line data released June 14, 2017 - primary endpoint met. Additional Phase 3 trial planned.
Phase 2 top-line data released October 3, 2017 - primary endpoint met (borderline) - p=0.05. Follow up analysis identfied p value = 0.036. Phase 3 trial planned.
Phase 2 initiated October 2016.
Hepatocellular carcinoma (HCC) - cancer

Latest News

  1. RedHill closes $20M public offering to prep commercialization of new drug
  2. RedHill Biopharma Announces Closing of $20 Million Underwritten Offering
  3. RedHill Biopharma Announces Pricing of $20 Million Underwritten Offering
  4. RedHill Biopharma Announces Proposed Public Offering of its American Depositary Shares
  5. RedHill Biopharma's antibiotic succeeds in late-stage study
  6. RedHill Biopharma Announces Positive Top-Line Results from Confirmatory Phase 3 Study with TALICIA® for H. pylori Infection
  7. RedHill Biopharma to Present at BMO 2018 Prescriptions for Success Healthcare Conference
  8. IntelGenx's NDA Resubmission for Rizaport Gets FDA Acceptance
  9. RedHill Biopharma Announces Presentation on YELIVA® (opaganib) for Multiple Myeloma at EORTC-NCI-AACR Symposium
  10. RedHill Biopharma Reports Third Quarter 2018 Financial Results and Business Highlights
  11. RedHill Biopharma to Host Third Quarter 2018 Financial Results Conference Call on November 13, 2018
  12. RedHill Biopharma to Host Analyst and Investor Webcast on TALICIA® for H. pylori infection on October 30, 2018
  13. RedHill Biopharma to Present at the BIO-Europe 2018 Conference
  14. RedHill Biopharma Announces Final Patient Assessed in Confirmatory Phase III Study with TALICIA® for H. pylori Infection
  15. RedHill Biopharma Announces Additional Data from Positive Phase III Study of RHB-104 in Crohn’s Disease at United European Gastroenterology (UEG) Week 2018
  16. Analysis: Positioning to Benefit within ScanSource, EMCORE, PRA Group, Aqua Metals, Compass Minerals International, and Redhill Biopharma — Research Highlights Growth, Revenue, and Consolidated Results
  17. RedHill Biopharma Late-Breaking Abstract on Positive Phase III Crohn’s Disease Study with RHB-104 to be Presented at UEG Week 2018
  18. RedHill Biopharma to Present at Ladenburg Thalmann 2018 Healthcare Conference